$UCB #UCB S.A. UCB : Bimekizumab looks like a game-changer, Buy vs Neutral: &gt;Bimekizumab enters with a bang - At the American Academy of Dermatology (AAD) congress this weekend, UCB presented the detailed data of two phase III trials on… https://t.co/xoAOrRu0Pt #equity #stocks https://t.co/KvY3kAFDHX